skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Optimal therapy in Gaucher disease

Review

(1984) Views  (908) Full article downloads

Authors: Ozlem Goker-Alpan

Published Date July 2010 Volume 2010:6 Pages 315 - 323
DOI: http://dx.doi.org/10.2147/TCRM.S6955

Ozlem Goker-Alpan

Lysosomal Diseases Research and Treatment Unit, Center for Clinical Trials, O&O Alpan LLC, Springfield, VA, USA

Abstract: Gaucher disease (GD), the inherited deficiency of the lysosomal enzyme glucocerebrosidase, presents with a wide range of symptoms of varying severity, and primarily affects the skeletal, hematologic and nervous systems. To date, the standard of care has included enzyme replacement therapy with imiglucerase. Although imiglucerase is highly effective in reversing the visceral and hematologic manifestations, skeletal disease is slow to respond, pulmonary involvement is relatively resistant, and the CNS involvement is not impacted. Because of the recent manufacturing and processing problems, the research and development of alternative therapeutics has become more pressing. The divergent phenotypes and the heterogeneity involving different organ systems implicates the involvement of several pathological processes that include enzyme deficiency, substrate accumulation, protein misfolding, and macrophage activation, that differ in each patient with GD. Thus, the therapy should be tailored individually in order to target multiple pathways that interplay in GD.

Keywords: glucocerebrosidase, enzyme replacement therapy, substrate reduction therapy, protein misfolding and chaperone therapy, macrophage






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
Optimal management of carpal tunnel syndrome
Living conditions, including life style, in primary-care patients with nonacute, nonspecific spinal pain compared with a population-based sample: a cross-sectional study
Gaucher disease: clinical profile and therapeutic developments
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Imiglucerase in the treatment of Gaucher disease: a history and perspective
New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
Role of gabapentin enacarbil XR in restless legs syndrome